Murlentamab Biosimilar - Research Grade

Human

AMHR2

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q16671

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of murlentamab, supplied for research use only and built around the anti-Müllerian hormone receptor type 2 (AMHR2 / AMHRII) target. It is a human IgG1, kappa antibody that binds AMHRII, mirroring the specificity of the originator molecule so investigators can study AMHRII engagement without sourcing clinical material. It is not the therapeutic drug and is not intended for human or veterinary use. The analog is useful as a positive binding control, a reference reagent for AMHRII-directed assays, a benchmarking tool in ADCC/ADCP and Fc-engineering work, and a starting point for antibody-drug-conjugate or bispecific development against AMHRII. Because it targets a defined tumor-associated receptor re-expressed in gynecologic cancers, it supports in-vitro characterization of AMHRII-positive cell lines and preclinical model work. The material is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support screening, assay development, and scale-up. AMHR2 (AMHRII), UniProt Q16671, is the dedicated type II receptor for anti-Müllerian hormone (AMH), a member of the TGF-beta superfamily. It is a single-pass transmembrane serine/threonine kinase receptor. On AMH binding, AMHR2 recruits and transphosphorylates a type I receptor (such as ALK2/ALK3/ALK6), which propagates the signal through SMAD1/5/8 to regulate transcription. Physiologically, AMHR2 drives regression of the Müllerian ducts during male sexual differentiation and contributes to ovarian follicle regulation; loss-of-function variants cause persistent Müllerian duct syndrome type II. AMHR2 expression is normally restricted to reproductive tissues, but it is aberrantly re-expressed in gynecologic malignancies including ovarian cancer, making it an attractive tumor-associated target for antibody-based approaches.

Anti-Muellerian hormone type II receptor, AMH type II receptor, MIS type II receptor, MISRII, MRII, Anti-Muellerian hormone type-2 receptor, AMHR, MISR2

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Murlentamab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Murlentamab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Murlentamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Murlentamab that binds AMHR2; for research use only.